Iduna Therapeutics is developing epigenetic reprogramming therapies that allow the rejuvenation and replacement of tissues that cannot regenerate themselves after injury or degeneration. This could permit regeneration without external tissue or surgery. David Sinclair, Steve Horvath, Juan Carlos Izpisua Belmonte, and Manuel Serrano are contributing to this effort.
According to a February 2021 press release, Iduna holds a license from Harvard University, which covers a patented gene therapy delivery system for the expression of specific factors known to induce pluripotency and rejuvenation.
Related Nature study from the Sinclair lab: Reprogramming to recover youthful epigenetic information and restore vision